Platinum
- Generic Name
- Platinum
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallop...
- Associated Conditions
- -
- Associated Therapies
- -
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT06648200
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 30
- Registration Number
- NCT06256237
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-30
- Target Recruit Count
- 24
- Registration Number
- NCT06128460
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 445
- Registration Number
- NCT05844150
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 160
- Registration Number
- NCT04502641
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04453930
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, China
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT04420884
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT03731442
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 397
- Registration Number
- NCT03607539
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03567642
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.